Original Article

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma

Abstract

Background: Chemotherapy with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD regimen) cannot cure all patients with Hodgkin lymphoma. In this study, we evaluated the efficacy and adverse effect of a new regimen consist irinotecan, cisplatin, and dexamethasone (ICD) in relapsed and refractory Hodgkin lymphoma as the second to fifth line of treatment.

Materials and Methods: We performed a retrospective study in 26 relapsed or refractory patients with Hodgkin lymphoma receiving at least the first-line chemotherapy regimen (ABVD) and (ICD) as salvage therapy in Thaleghany Hospital from 2012 to 2018. This regimen consisted of irinotecan 65mg/m2 D1, D8, cisplatin 30mg/m2 D1, D8, and dexamethasone 40mg D1, 2, 8, and 9 was administered every 3 weeks for 6 cycles.  Treatment was discontinued in cases of disease progression or severe toxicity. Response to treatment was evaluated after two cycles. Patients with complete and partial remission were candidate high dose chemotherapy and autologous stem cell transplantation. Twenty-four patients were enrolled in the study. The mean age of 22 patients was 31.5 (19-67) years. Seven patients (29.1%) were in the first recurrence, and 17 (70.8%) were in the second or subsequent recurrence.

Results: According to this study, three patients (12.5%) had complete response, 13 (45%) had partial response, four (16.6%) had stable disease, and four (16.6%) had progressive disease. Nine patients (37.5%) received high-dose chemotherapy and autologous stem cell support after ICD regimen. None of the cycles of chemotherapy were delayed due to treatment-related adverse event. Overall survival after six months in all patients was 91%, and mortality rate was 8.3% at the end of the study.

Conclusion: The goal of salvage chemotherapy in relapsed or refractory Hodgkin Lymphoma is achieving CR or PR preparation patients for stabilization with BMT. Thus, we recommend ICD as one of the most effective protocols with overall response rate of 66% in this population.

 

 

1. De González AB, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22):2071-7.
2. Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998;339(21):1506-14
3. Oza A, Ganesan T, Leahy M, et al. Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. Ann Oncol. 1993;4(5):385-92.
4. Abalı H, Ürün Y, Öksüzoğlu B, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest. 2008;26(4):401-6.
5. Mohammad ali M, Hossein R, Behrooz N, et al. IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma. Int J Hematol-Oncol. Stem Cell Res. 2011;5(3):11-15.
6. Portlock CS, Rosenberg SA, Glatstein E, et al. Impact of Salvage Treatment on Initial Relapses in Patients With Hodgkin Disease, Stages I–III. Blood. 1978;51(5):825-33.
7. Suzumiya J, Suzushima H, Maeda K, et al. Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma. Int J Hematol. 2004;79(3):266-70.
8. Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression‐free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer. 2006;106(2):353-60.
9. Ghadiany M, Foratyazdi M, Rahimi H, et al. Modified irinotecan plus cisplatin and dexamethasone (icd) combination chemotherapy as salvage chemotherapy for patients with relapsed/refractory diffuse large cell lymphoma. Indian J Hematol Blood Transfus. 2014;30(4):265-8.
10. Kang HJ, Kim WS, Suh C, et al. Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. Cancer Chemother Pharmacol. 2008;62(2):299-304.
11. Suyanı E, Sucak GT, Akı ŞZ, et al. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol. 2011;90(6):685-91.
12. Bartlett NL, Niedzwiecki D, Johnson J, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071-9.
13. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35-41.
14. Moskowitz AJ, Hamlin Jr PA, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456-60.
15. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-68.
16. Knopińska-Posłuszny W, Kulikowski W, Paszkiewicz-Kozik E, et al. Zastosowanie bendamustyny z gemcytabiną i deksametazonem w leczeniu pierwotnie opornej i nawrotowej postaci chłoniaka Hodgkina–wieloośrodkowe badanie obserwacyjne Polskiej Grupy Badawczej Chłoniaków (PLRG). Acta Haematol Pol. 2015;46:58-9.
17. Wagener DT, Verdonk H, Dirix L, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol. 1995;6(2):129-32.
18. Urushihata K, Koizumi T, Kaneki T, et al. Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma. Internl Med. 2002;41(8):648-50.
19. Niitsu N, Kohori M, Higashihara M, et al. Phase II study of the irinotecan (CPT‐11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T‐cell lymphoma. Cancer Sci. 2007;98(1):109-12.
Files
IssueVol 17, No 3 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijhoscr.v17i3.13309
Keywords
Relapse; Refractory; Hodgkin lymphoma; Irinotecan; Cisplatin; Salvage chemotherapy
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Tabarraee M, Rezaee A, Abolghasemi S, Ghadiany M, Tavakoli Ardakani M, Mahdizadeh M, Hamidi N, Ghasemi K. Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma. Int J Hematol Oncol Stem Cell Res. 2023;17(3):194-199.